Synergetic interactions between rehabilitation and pharmacotherapy in COPD

Clinical and Investigative Medicine

Volumn 29, Issue 3, 2006, Pages 170-177

  Pépin, Véronique ^a   Laviolette, Louis ^a   Saey, Didier ^a   Maltais, François ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; CYCLING; DRUG POTENTIATION; HUMAN; LEG EXERCISE; MUSCLE FATIGUE; PRIORITY JOURNAL; QUALITY OF LIFE;

EXERCISE; EXERCISE THERAPY; FATIGUE; HEALTH STATUS; HUMANS; MODELS, BIOLOGICAL; PHYSICAL ENDURANCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 33745250087     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (47)

1. O'Donnell DE, Aaron S, Bourbeau J, et al. State of the Art Compendium: Canadian Thoracic Society recommendations for the management of chronic obstructive pulmonary disease. Can Respir J 2004;11 Suppl B:7B-59B.
2. Sin DD. Man SFP. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-9.
3. Jones PW. Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997;155:1283-9.
4. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957-65.
5. Dahl R, Greefhorst LAPM, Nowak D, et al. Inhaled Formoterol Dry Powder Versus Ipratropium Bromide in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2001;164:778-84.
6. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23:832-40.
7. O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004;24:86-94.
8. Maltais F, Hamilton A, Marciniuck D, et al. Improvements in symptom-limited exercise performance over eight hours with once-daily Tiotropium in patients with COPD. Chest 2005;128:1168-78.
9. Donohue JF, van Noord JA, Bateman ED, et al. A 6-Month, Placebo-Controlled Study Comparing Lung Function and Health Status Changes in COPD Patients Treated With Tiotropium or Salmeterol*. Chest 2002;122:47-55.
10. Vincken W, Van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19:209-16.
11. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-456.
12. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:542-9.
13. Killian KJ, Leblanc P, Martin DH, Summers E, Jones NL, Campbell EJM. Exercise capacity and ventilatory, circulatory, and symptom limitation in patients with airflow limitation. Am Rev Respir Dis 1992;146:935-40.
14. Pepin V, Saey D, Whittom F, LeBlanc P, Maltais F. Walking Versus Cycling: Sensitivity to Bronchodilation in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2005;72:1517-22.
15. Mador MJ, Kufel TJ, Pineda L. Quadriceps fatigue following cycle exercise in patients with COPD. Am J Respir Crit Care Med 2000;161:447-53.
16. Saey D, Debigaré R, LeBlanc P, et al. Contractile leg fatigue after cycle exercise: a factor limiting exercise in patients with COPD. Am J Respir Crit Care Med 2003;168:425-30.
17. Mador MJ, Bozkanat E, Kufel TJ. Quadriceps fatigue after cycle exercise in patients with COPD compared with healthy control subjects. Chest 2003;123:1104-11.
18. O'Donnell, D. E., Hamilton, A., Kesten, S. Influence of the Exercise-Limiting Symptom on the Relationship between Lung Hyperinflation and Endurance Time in COPD Patients Treated with Tiotropium. Am J Resp Crit Care Med 2005;171:A314.
19. Gosselink R, Troosters T, Decramer M. Peripheral muscle weakness contributes to exercise limitation in COPD. Am J Respir Crit Care Med 1996;153:976-80.
20. Bernard S, Leblanc P, Whittom F, et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:629-34.
21. Coronell C, Orozco-Levi M, Mendez R, Ramirez-Sarmiento A, Galdiz JB, Gea J. Relevance of assessing quadriceps endurance in patients with COPD. Eur Respir J 2004;24:129-36.
22. Hamilton AL, Killian KJ, Summers E, Jones NL. Muscle strength, symptom intensity and exercise capacity in patients with cardiorespiratory disorders. Am J Respir Crit Care Med 1995;152:2021-31.
23. Whittom F, Jobin J, Simard PM, et al. Histochemical and morphological characteristics of the vastus lateralis muscle in COPD patients. Comparison with normal subjects and effects of exercise training. Med Sci Sports Exerc 1998;30:1467-74.
24. Gosker HR, van Mameren H, van Dijk PJ, et al. Skeletal muscle fibre-type shifting and metabolic profile in patients with chronic obstructive pulmonary disease. Eur Respir J 2002;19:617-25.
25. Jakobsson P, Jorfeldt L, Henriksson J. Metabolic enzyme activity in the quadriceps femoris muscle in patients with severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;151:374-7.
26. Maltais F, Simard AA, Simard C, Jobin J, Desgagnés P, Leblanc P. Oxidative capacity of the skeletal muscle and lactic acid kinetics during exercise in normal subjects and in patients with COPD. Am J Respir Crit Care Med 1996;153:288-93.
27. Allaire J, Maltais F, Doyon JF, et al. Peripheral muscle endurance and the oxidative profile of the quadriceps in patients with COPD. Thorax 2004;59:673-8.
28. Saey D, Michaud A, Couillard A, et al. Contractile fatigue, muscle morphometry, and blood lactate in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:1109-15.
29. Couillard A, Maltais F, Saey D, et al. Exercise-induced quadriceps oxidative stress and peripheral muscle dysfunction in patients with COPD. Am J Respir Crit Care Med 2003;167:1664-9.
30. Couillard A. Prefaut C. From muscle disuse to myopathy in COPD: potential contribution of oxidative stress. Eur Respir J 2005;26:703-19.
31. Koechlin C, Couillard A, Simar D, et al. Does oxidative stress alter quadriceps endurance in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 2004;169:1022-7.
32. Bernard S, Whittom F, Leblanc P, et al. Aerobic and strength training in patients with COPD. Am J Respir Crit Care Med 1999;159:896-901.
33. Ortega F, Toral J, Cejudo P, et al. Comparison of effects of strength and endurance training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:669-74.
34. Mador MJ, Bozkanat E, Aggarwal A, Shaffer M, Kufel TJ. Endurance and Strength Training in Patients With COPD. Chest 2004;125:2036-45.
35. Maltais F, Leblanc P, Simard C, et al. Skeletal muscle adaptation to endurance training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;154:442-7.
36. Casaburi R, Patessio A, Ioli F, Zanaboni S, Donner CF, Wasserman K. Reductions in exercise lactic acidosis and ventilation as a result of exercise training in patients with obstructive lung disease. Am Rev Respir Dis 1991;143:9-18.
37. Maltais F, Leblanc P, Jobin J, et al. Intensity of training and physiologic adaptation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997;155:555-61.
38. Mador MJ, Kufel TJ, Pineda LA, et al. Effect of pulmonary rehabilitation on quadriceps fatigu-ability during exercise. Am J Respir Crit Care Med 2001;163:930-5.
39. Gigliotti F, Coli C, Bianchi R, et al. Exercise Training Improves Exertional Dyspnea in Patients With COPD: Evidence of the Role of Mechanical Factors. Chest 2003;123:1794-802.
40. Porszasz J, Emtner M, Goto S, Somfay A, Whipp BJ, Casaburi R. Exercise Training Decreases Ventilatory Requirements and Exercise-Induced Hyperinflation at Submaximal Intensities in Patients With COPD. Chest 2005;128:2025-34.
41. Casaburi R, Kukafka D, Cooper CB, Witek TJ, Jr., Kesten S. Improvement in Exercise Tolerance With the Combination of Tiotropium and Pulmonary Rehabilitation in Patients With COPD. Chest 2005;127:809-17.
42. Emtner M, Porszasz J, Burns M, Somfay A, Casaburi R. Benefits of supplemental oxygen in exercise training in nonhypoxemic chronic obstructive pulmonary disease patients. Am J Respir Crit Care Med 2003;168:1034-42.
43. Palange P, Valli G, Onorati P, et al. Effect of heliox on lung dynamic hyperinflation, dyspnea, and exercise endurance capacity in COPD patients. J Appl Physiol 2004;97:1637-42.
44. Ambrosino N. Strambi S. New strategies to improve exercise tolerance in chronic obstructive pulmonary disease. Eur Respir J 2004;24:313-22.
45. Casaburi R, Bhasin S, Cosentino L, et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:870-8.
46. Marquis K, Debigaré R, LeBlanc P, et al. Mid-thigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with COPD. Am J Respir Crit Care Med 2002;166:809-13.
47. Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 2005;82:53-9.